source
- Odyssey, on second try, snags $279M in an IPOAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…BioPharma Dive · 3mo ago↗ source
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 3mo ago↗ source
- Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers“Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study foundSTAT · 3mo ago